David Sourdive

Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices.

Mablink Bioscience is a biotechnology company based in Lyon, France that develops next-generation antibody-drug conjugates for the treatment of solid tumors. Mablink Bioscience's exclusive PSarlink™ platform is a unique stealth technology that "masks" the hydrophobicity of the cytotoxic drugs by adding a polysarcosine chain to the linker. The French company's pipeline is built on the topoisomerase-I inhibitor exatecan as a payload for current developments. Recently, the company announced the publication of a review article titled “Payload Diversification\: A Key Step in the Development of Antibody–Drug Conjugates” which reviews the history of the successes and failures in ADC payloads and takes a look at the new roads currently explored by the industry. The company was founded in 2018 by Warren Viricel and Jean-Guillaume Lafay, with Jean-Guillaume Lafay serving as CEO since then.

Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices.

Bilhi Genetics SAS specializes in the development of predictive medicines. It offers products for hepatic fibrosis and skin scars. The company was founded by David Sourdive and Pierre Dessein in June 2012 and is headquartered in Marseille, France.

Nextbiotix SAS operates as clinical-stage Biopharmaceutical Company, which develops probiotics. The company was founded by Benjamin Hadida, Harry Sokol, Philippe Langella and Patrick Gervais in 2016 and is headquartered in Dijon, France.

Cell-Easy SAS operates as a stem cell contract development and manufacturing organization. It offers ready-to-inject adipose-derived allogeneic stem cells for preclinical and clinical drug development projects. The company is headquartered in Toulouse, France.

Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices.

Nextbiotix SAS operates as clinical-stage Biopharmaceutical Company, which develops probiotics. The company was founded by Benjamin Hadida, Harry Sokol, Philippe Langella and Patrick Gervais in 2016 and is headquartered in Dijon, France.

Nextbiotix SAS operates as clinical-stage Biopharmaceutical Company, which develops probiotics. The company was founded by Benjamin Hadida, Harry Sokol, Philippe Langella and Patrick Gervais in 2016 and is headquartered in Dijon, France.

Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices.

Mablink Bioscience is a biotechnology company based in Lyon, France that develops next-generation antibody-drug conjugates for the treatment of solid tumors. Mablink Bioscience's exclusive PSarlink™ platform is a unique stealth technology that "masks" the hydrophobicity of the cytotoxic drugs by adding a polysarcosine chain to the linker. The French company's pipeline is built on the topoisomerase-I inhibitor exatecan as a payload for current developments. Recently, the company announced the publication of a review article titled “Payload Diversification\: A Key Step in the Development of Antibody–Drug Conjugates” which reviews the history of the successes and failures in ADC payloads and takes a look at the new roads currently explored by the industry. The company was founded in 2018 by Warren Viricel and Jean-Guillaume Lafay, with Jean-Guillaume Lafay serving as CEO since then.

Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices.

Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices.

Cell-Easy SAS operates as a stem cell contract development and manufacturing organization. It offers ready-to-inject adipose-derived allogeneic stem cells for preclinical and clinical drug development projects. The company is headquartered in Toulouse, France.

Nextbiotix SAS operates as clinical-stage Biopharmaceutical Company, which develops probiotics. The company was founded by Benjamin Hadida, Harry Sokol, Philippe Langella and Patrick Gervais in 2016 and is headquartered in Dijon, France.

Mablink Bioscience is a biotechnology company based in Lyon, France that develops next-generation antibody-drug conjugates for the treatment of solid tumors. Mablink Bioscience's exclusive PSarlink™ platform is a unique stealth technology that "masks" the hydrophobicity of the cytotoxic drugs by adding a polysarcosine chain to the linker. The French company's pipeline is built on the topoisomerase-I inhibitor exatecan as a payload for current developments. Recently, the company announced the publication of a review article titled “Payload Diversification\: A Key Step in the Development of Antibody–Drug Conjugates” which reviews the history of the successes and failures in ADC payloads and takes a look at the new roads currently explored by the industry. The company was founded in 2018 by Warren Viricel and Jean-Guillaume Lafay, with Jean-Guillaume Lafay serving as CEO since then.

Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices.

Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices.

Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices.

Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices.

Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices.

Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices.

Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices.

Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices.

Mablink Bioscience is a biotechnology company based in Lyon, France that develops next-generation antibody-drug conjugates for the treatment of solid tumors. Mablink Bioscience's exclusive PSarlink™ platform is a unique stealth technology that "masks" the hydrophobicity of the cytotoxic drugs by adding a polysarcosine chain to the linker. The French company's pipeline is built on the topoisomerase-I inhibitor exatecan as a payload for current developments. Recently, the company announced the publication of a review article titled “Payload Diversification\: A Key Step in the Development of Antibody–Drug Conjugates” which reviews the history of the successes and failures in ADC payloads and takes a look at the new roads currently explored by the industry. The company was founded in 2018 by Warren Viricel and Jean-Guillaume Lafay, with Jean-Guillaume Lafay serving as CEO since then.

Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices.

Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices.

Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices.

Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices.

Mablink Bioscience is a biotechnology company based in Lyon, France that develops next-generation antibody-drug conjugates for the treatment of solid tumors. Mablink Bioscience's exclusive PSarlink™ platform is a unique stealth technology that "masks" the hydrophobicity of the cytotoxic drugs by adding a polysarcosine chain to the linker. The French company's pipeline is built on the topoisomerase-I inhibitor exatecan as a payload for current developments. Recently, the company announced the publication of a review article titled “Payload Diversification\: A Key Step in the Development of Antibody–Drug Conjugates” which reviews the history of the successes and failures in ADC payloads and takes a look at the new roads currently explored by the industry. The company was founded in 2018 by Warren Viricel and Jean-Guillaume Lafay, with Jean-Guillaume Lafay serving as CEO since then.

Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices.

Nextbiotix SAS operates as clinical-stage Biopharmaceutical Company, which develops probiotics. The company was founded by Benjamin Hadida, Harry Sokol, Philippe Langella and Patrick Gervais in 2016 and is headquartered in Dijon, France.

Mablink Bioscience is a biotechnology company based in Lyon, France that develops next-generation antibody-drug conjugates for the treatment of solid tumors. Mablink Bioscience's exclusive PSarlink™ platform is a unique stealth technology that "masks" the hydrophobicity of the cytotoxic drugs by adding a polysarcosine chain to the linker. The French company's pipeline is built on the topoisomerase-I inhibitor exatecan as a payload for current developments. Recently, the company announced the publication of a review article titled “Payload Diversification\: A Key Step in the Development of Antibody–Drug Conjugates” which reviews the history of the successes and failures in ADC payloads and takes a look at the new roads currently explored by the industry. The company was founded in 2018 by Warren Viricel and Jean-Guillaume Lafay, with Jean-Guillaume Lafay serving as CEO since then.

Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices.

Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices.